Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$1.5 billion.

  • Lyell Immunopharma's Retained Earnings fell 2824.04% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 2824.04%. This contributed to the annual value of -$1.3 billion for FY2024, which is 3422.71% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Retained Earnings stood at -$1.5 billion, which was down 2824.04% from -$1.4 billion recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Retained Earnings ranged from a high of -$451.8 million in Q2 2021 and a low of -$1.5 billion during Q3 2025
  • In the last 5 years, Lyell Immunopharma's Retained Earnings had a median value of -$923.8 million in 2023 and averaged -$948.6 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 7488.38% in 2021, then plummeted by 2149.1% in 2024.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Retained Earnings stood at -$584.4 million in 2021, then tumbled by 31.34% to -$767.5 million in 2022, then tumbled by 30.57% to -$1.0 billion in 2023, then plummeted by 34.23% to -$1.3 billion in 2024, then dropped by 9.94% to -$1.5 billion in 2025.
  • Its Retained Earnings stands at -$1.5 billion for Q3 2025, versus -$1.4 billion for Q2 2025 and -$1.4 billion for Q1 2025.